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(anti-TNF) agents has changed the way of treating IBD. 
Anti-TNF therapy allows not only a rapid improvement 
of symptoms, but also MH  [2] . Accumulating evidence 
indicates that MH may change the course of both Crohn’s 
disease (CD) and ulcerative colitis (UC)  [3–5] . Accord-
ingly, MH is now regarded as an important treatment end 
point in clinical trials and is increasingly used in the clin-
ical management of IBD  [6] . 
 After discussing current definitions of MH, we will 
review the efficacy of anti-TNF antibodies in inducing 
and maintaining MH, and then highlight the positive im-
pact of MH on long-term outcomes in IBD.
 Defining Mucosal Healing 
 MH is usually assessed by ileocolonoscopy or proc-
tosigmoidoscopy in CD and UC, respectively. However, 
the definition of MH varies across studies and there is 
no validated definition of MH or endoscopic remission 
in IBD  [7, 8] . Various definitions have been used in CD 
in clinical trials and referral-center-based studies ( ta-
ble 1 ,  2 ): the absence of mucosal ulcerations and ulcers 
 [9, 10] or the absence of ulcerations at follow-up endo-
scopy in patients in whom ulcerations were present at 
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 Abstract 
 Nowadays, mucosal healing is regarded as a major end point 
in clinical trials and is increasingly used in clinical practice for 
the management of patients with inflammatory bowel dis-
ease. The definition of mucosal healing varies across studies 
and validated endoscopic scoring indices are still lacking. 
The advent of anti-tumor necrosis factor agents has changed 
the way of treating inflammatory bowel disease and high 
rates of induction and maintenance of mucosal healing can 
be achieved with this drug class. Mucosal healing is desirable 
as it may change the natural course of the disease by de-
creasing surgery and hospitalization rates in both ulcerative 
colitis and Crohn’s disease.  Copyright © 2012 S. Karger AG, Basel 
 The initial lack of a correlation between mucosal heal-
ing (MH) and clinical remission in patients with inflam-
matory bowel disease (IBD) led clinicians to abandon this 
concept  [1] . The advent of anti-tumor necrosis factor
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baseline ileocolonoscopy  [11] . The definition of MH in 
CD as the total disappearance of ulcers is simple in clin-
ical practice, but this binary statement does not take 
into account patients with evidence of MH under treat-
ment with some remaining lesions, like erosions. For 
UC, the International Organization of IBD made a con-
sensus in 2007 to define MH: the absence of friability, 
blood, erosions and ulcers in all visualized segments of 
the gut mucosa  [12] . Presence of abnormal vascular pat-
tern is compatible with MH according to panel experts 
 [12] .
 For the assessment of MH, clinicians require repro-
ducible and validated scoring indices of disease activity 
( table  1 )  [12] . There are three main endoscopic disease 
activity indices used in clinical trials for CD: the Crohn’s 
Disease Endoscopic Index of Severity (CDEIS)  [13] , the 
Simple Endoscopic Score for Crohn’s Disease (SES-CD) 
 [14] and the Rutgeerts score  [15] . The CDEIS is a prospec-
tively built scoring index, based on elementary CD le-
sions and the percentage of involvement of different ileo-
colonic segments  [13] . The CDEIS, considered as the gold 
standard scoring index, is regarded as complex and this 
limits its usefulness in clinical practice, largely restricting 
it to the clinical trial setting. A simple index, the SES-CD 
has been developed and correlates well with the CDEIS 
 [14] . SES-CD involves four variables: ulcer size, the extent 
of the ulcerated surface, the extent of the affected surface 
and stenosis in five bowel segments. However, the SES-
CD is not validated. For both indices, there is no validat-
ed cut-off value for defining endoscopic remission, re-
sponse or MH. Two cut-offs defining endoscopic remis-
sion (CDEIS  ! 6) and complete MH (CDEIS  ! 4) have been 
proposed  [16] . 
 The Rutgeerts score is used in the postoperative set-
ting to determine the presence and severity of endoscop-
ic disease recurrence in the neoterminal ileum after ileal 
or ileocolonic resection  [9] . Scoring is based on the pres-
ence of aphthous lesions, inflamed mucosa, nodules and 
narrowing, and ranges from i0 to i4 accordingly  [9] . Most 
clinical trials have used i2 as a cut-off to define endoscop-
ic recurrence. However, the Rutgeerts score still lacks val-
idation. 
 In the small bowel, capsule endoscopy is increasingly 
used to assess the severity of CD  [17] . Specific disease ac-
tivity indices have been developed, but still await valida-
tion before using them in clinical trials and/or clinical 
practice  [18] .
 For UC, the first index was developed by Truelove and 
Witts  [19]  in a placebo-controlled trial on cortisone treat-
ment. Thereafter, several endoscopic system scoring sys-
tems have been developed (e.g. the modified Baron score 
 [20] and the Mayo endoscopic subscore  [21] ) but none of 
them have been fully validated ( table 2 ). Recently, Travis 
et al.  [22] proposed a new endoscopic score, namely the 
Ulcerative Colitis Endoscopic Index of Severity. Develop-
ment of this index was made in two phases in order to 
assess intra- and inter-individual variation in the overall 
endoscopic assessment of severity  [22] . One of the major 
differences with the Mayo endoscopic subscore is the ex-
clusion of the item ‘friability’ from the endoscopic de-
scription of severity  [22] . This score is composed of the 
following items: vascular pattern, bleeding, erosions and 
Table 1.  Main clinical trials with anti-TNF agents using MH as a primary or secondary end point in CD
Study name [ref.] Study design Anti-TNF agent Endoscopic index used MH definition
ACCENT 1
(endoscopic substudy) 
[10]
multicenter, randomized, 
double-blind, controlled study
infliximab CDEIS complete absence of mucosal
ulcerations that were observed at 
baseline
SONIC [24] multicenter, randomized, 
double-blind, controlled study
infliximab No score used - only a 
descriptive evaluation
complete absence of mucosal
ulceration in the colon and terminal 
ileum
D’Haens et al. [30] multicenter, open-label, 
randomized study
infliximab SES-CD no ulcers
MUSIC [16] multicenter, open-label 
study
certolizumab CDEIS absence of ulcers; endoscopic 
remission defined as CDEIS <6
EXTEND [9] randomized, double blind, 
placebo-controlled study
adalimumab SES-CD absence of mucosal ulceration
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ulcers; once it has been validated independently, it should 
be used mainly in clinical trials and clinical practice in 
the future  [22] .
 Induction and Maintenance of Mucosal Healing with 
Anti-TNF Agents 
 Induction 
 In the ACCENT 1  [23] trial, a randomized controlled 
trial evaluating the efficacy of infliximab for the treat-
ment of refractory active CD, an endoscopic substudy  [10] 
of 99 patients was performed. MH was observed at week 
10 in 29% of patients (13/45) who had received induction 
therapy with three infusions of infliximab compared 
with 3% of patients (1/29, p = 0.006) who had received 
only one infusion at baseline  [10] . Systematic mainte-
nance therapy with infliximab therapy every 8 weeks al-
lowed MH in 44% (16/36) of CD patients at week 54 com-
pared to 18% (4/22, p = 0.041) in patients treated episod-
ically  [10] . In the SONIC trial, which compared infliximab 
monotherapy, azathioprine monotherapy and combined 
infliximab and azathioprine therapy for active luminal 
CD, MH was significantly higher in the combined arm 
(44%, p  ! 0.001) at week 26  [24] .
 The MUSIC trial is an open-label study that assessed 
the ability of certolizumab pegol to induce MH at 10 
weeks in 89 CD patients with active disease  [16] . Induc-
tion therapy consisted of subcutaneous injection at weeks 
0, 2 and 4 followed by 1 injection at week 8. At 10 weeks, 
endoscopic remission (defined as CDEIS  ! 6) was seen in 
42%, but MH (defined as an absence of ulcers) was seen 
in only 5% of patients  [16] . The EXTEND trial, evaluat-
ing the efficacy of adalimumab for the treatment of mod-
erate to severe active ileocolonic CD, used MH at week 
12 as a primary end point  [9] . One hundred and thirty-
five CD patients received 160-mg and 80-mg induction 
therapy at weeks 0 and 2, respectively, and were then ran-
domized at week 4 to blinded maintenance therapy with 
40 mg ada limumab every other week or placebo up to 
week 52. The primary end point was achieved in 27% 
(17/62) of the adalimumab arm compared with 13% 
(8/61) of the placebo-treated patients (p = 0.056)  [9] . At 
week 52, rates of MH were 24% and 0, respectively (p  ! 
0.001). Remission rates, based on CDEIS, were 52% for 
adalimumab and 28% for placebo at week 12 (p = 0.06) 
and 28 and 3%, respectively, at week 52 (p  ! 0.01)  [9] 
( fig. 1 ). 
 In the ACT-1 and ACT-2 trials (Active Ulcerative 
Colitis Trials 1 and 2),  [25, 26] infliximab or placebo 
were administered intravenously in 364 (in each study) 
patients with moderate to severe refractory UC. Induc-
tion therapy with infliximab 5 mg/kg given at weeks 0, 
2 and 6 resulted at week 8 in MH in 62% of patients in 
the ACT-1 trial and in 60.3% of patients in ACT-2 com-
pared with 33.9 and 30.9% in the placebo groups of each 
study (p  ! 0.001 in both trials)  [25, 26] . A small, open-
label study involving 20 patients evaluated the efficacy 
of adalimumab in patients with endoscopic evidence of 
active, moderate to severe, refractory UC  [27] . Induction 
treatment with adalimumab 160 mg at week 0, 80 mg at 
week 2 and 40 mg every other week resulted in MH in 
30% of patients at week 8  [27] . Finally, in the ULTRA 2 
trial  [28] , a randomized, double-blind, placebo-con-
trolled trial, the efficacy of adalimumab in UC patients 
for induction was evaluated  [28] . At week 8, MH was 
achieved in 41.1% of patients receiving adalimumab and 
31.7% of patients receiving placebo (p = 0.032)  [28] 
( fig. 2 ). 
 Maintenance 
 Anti-TNF agents have also demonstrated efficacy in 
maintaining MH in IBD patients. In the ACCENT 1 tri-
al  [23] , scheduled treatment strategy with infliximab 
Table 2.  Main clinical trials with anti-TNF agents using MH as a secondary end point in UC
Study name [ref.] Study design Anti-TNF agent Endoscopic index used MH definition
ACT-1 [25] multicenter, randomized, double-
blind, placebo-controlled study
infliximab Mayo endoscopic 
subscore
absolute subscore for endoscopy 
of 0 or 1
Afif et al. [27] multicenter, open-label study adalimumab Mayo endoscopic 
subscore
decrease in endoscopic subscore 
from 2 or 3 at baseline to 0 or 1
ULTRA 2 [28] multicenter, randomized, double-
blind, placebo-controlled trial
adalimumab Mayo endoscopic 
subscore
endoscopy subscore 0 or 1
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demonstrated sustained MH in almost 50% of treated 
patients at 1 year. Moreover, a greater proportion of pa-
tients with scheduled treatment achieved complete MH 
at week 54 compared to the episodic group (50 vs. 7%,
p = 0.007)  [29] . D’Haens et al.  [30] , demonstrated that 
early induction therapy with infliximab combined with 
azathioprine maintenance therapy resulted in a greater 
rate of MH at 14 weeks (73.1%) when compared to the 
step-up approach with steroids and azathioprine (30,4%, 
p = 0.0028)  [30] . In the EXTEND trial, a significant dif-
ference was observed in terms of MH at 1 year in the 
maintenance therapy group with adalimumab com-
pared to the placebo group (24 vs. 0%, respectively)  [9] 
( fig. 1 ).
 In the postoperative setting, anti-TNF also allows 
maintenance of MH. In a randomized study, Regueiro et 
al.  [31]  studied 24 patients with CD who had undergone 
ileocolonic resection to receive intravenous infliximab, 
which was administered within 4 weeks of surgery and 
continued for 1 year, or placebo. The rate of recurrence 
(Rutgeerts score  6 i2) at 1 year was significantly lower in 
the infliximab group (9.1%) compared to the placebo 
group (84.6%, p = 0.0006)  [31] . 
 For UC, in the ACT-1 trial, scheduled maintenance 
therapy with infliximab 5 mg/kg every 8 weeks resulted 
in MH in 45.5% of patients compared to 18.2% (p  ! 0.001) 
in the placebo group at week 54  [25] . In the ULTRA 2 
trial, MH in UC patients taking adalimumab every other 
week was achieved in 25 and 15.4% in the active arm and 
placebo group, respectively, (p = 0.032) at week 52 [28] 
( fig. 2 ).
 Impact of Mucosal Healing on the Disease Course 
 Clinical Response/Remission 
 In the ACCENT 1 trial, patients who achieved MH 
with infliximab had a longer relapse-free disease course 
than those without MH  [32] . Moreover, at week 54, a lon-
ger duration of clinical remission was observed in the 
complete MH group (20 weeks) compared to patients 
without complete MH (4 weeks)  [32] . In a substudy of the 
ACCENT 1 trial, MH at weeks 10 and 54 was associated 
with higher clinical remission rates up to week 54, al-
though these results were not statistically significant  [29] .
 A substudy of the ‘step-up/top-down’ trial focused on 
the value of the endoscopic assessment after 2 years of 
treatment on clinical outcomes at years 3 and 4. MH (de-
fined as an SES-CD score of zero) at 2 years predicted 
stable sustained clinical remission in the following 2 
years in 68 versus 35% of patients (p = 0.004) with endo-
scopic evidence of persistent disease activity (defined as 
an SES-CD score from 2 to 9)  [33] . In a large retrospective 
cohort study involving 214 CD patients on anti-TNF ther-
apy, Schnitzler et al.  [11]  evaluated the impact of MH on 
long-term outcomes. At 5 years, clinical remission was 
maintained in 65% (83/128) of patients with MH com-
pared to 40% (34/86) of patients who did not achieve MH 
(p = 0.0004)  [11] . 
 It has been demonstrated that the Rutgeerts score, 
which has become the gold standard for evaluating CD 
postoperative recurrence as the severity of endoscopic le-
sions at 1 year, is predictive of clinical recurrence  [15] . A 
total of 89 CD patients who had been treated by ileal re-
0
ACCENT 1 SONIC MUSIC EXTEND
5
10
15
20
30
35
40
45
%
25
0
ACT 1 ULTRA 2
10
20
40
50
60
70
%
30
 Fig. 1. Number (%) of CD patients achieving MH in clinical trials 
with anti-TNF agents. 
 Fig. 2. Number (%) of UC patients achieving MH in clinical trials 
with anti-TNF agents. 
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section were included in a prospective cohort study  [15] . 
Three years after surgery, the endoscopic recurrence rate 
was 85% and symptomatic recurrence occurred in 34% 
 [15] . Endoscopic disease often recurs after infliximab is 
stopped. In a prospective cohort study of 12 consecutive 
patients on a postoperative infliximab regimen, treat-
ment was stopped 3 years after surgery. Discontinuation 
of infliximab resulted in endoscopic recurrence at 4 
months in 10 of 12 patients (83%)  [34] . 
 For UC, similar findings were reported in a landmark 
study from 1966  [35] . Indeed, 40% of UC patients who 
achieved MH after acute treatment with oral and rectal 
corticosteroids remained asymptomatic during a 1-year 
follow-up  [35] , whereas only 18% of patients who did not 
achieve MH after treatment remained asymptomatic 
during the same period  [35] . In the ACT-1 and ACT-2 tri-
als  [25, 26] , the proportion of patients in clinical remis-
sion at week 30 of therapy was 4-fold greater for patients 
with MH at week 8 (48.3 vs. 9.5%, respectively). 
 Overall, these findings suggest that MH is associated 
with both a higher clinical response and lower relapse 
rates in both CD and UC  [36] .
 Hospitalizations  
 In the endoscopic substudy of the ACCENT I trial, pa-
tients achieving MH at both weeks 10 and 54 needed less 
CD-related hospitalizations (0%) compared to those with 
MH at only one of two visits (18.8%) or with no healing 
at either visit (28%)  [29] . In a retrospective single-center 
cohort study evaluating the long-term outcome of inflixi-
mab in 214 patients with CD, patients who achieved MH 
needed hospitalization less frequently than patients who 
did not achieve it (42.2 vs. 59.3%, respectively, p = 0.0018) 
 [11] .
 For UC, Ardizzone et al.  [37]  showed that no MH after 
the first course of corticosteroid therapy was associated 
with a more aggressive disease course. Indeed, after mul-
tivariate analysis, lack of MH was the only factor associ-
ated with negative outcomes at 5 years, including hospi-
talization (HR 3.634, 95% CI 1.556–8.485, p = 0.0029) 
 [37] . 
 Thus, MH is associated with lower hospitalization 
rates in both UC and CD  [36] .
 Surgery 
 Extensive and deep ulcerations in CD patients pre-
dicted a more aggressive clinical course with increased 
rates of penetrating complications and surgery  [38] . In a 
retrospective single-center cohort study, Schnitzler et al. 
 [11]  found that patients who had MH on an infliximab 
regimen needed less abdominal surgeries than those 
who did not achieve MH [14.1 (12/89) vs. 38.4% (33/86), 
respectively; p  ! 0.0001]. In a Norwegian population-
based cohort study involving 458 IBD patients, a greater 
proportion of CD patients [11% (6/53)] who achieved MH 
at 1 year were able to avoid surgical resection over a pe-
riod of 5 years compared to 20% (18/88) who were with-
out MH at 1 year (p = 0.10)  [39] . Regarding UC, 2% of 
patients with MH at 1 year needed a surgical resection in 
5 years compared to 7% of patients without MH (p = 
0.02)  [39] .
 In a retrospective single-center study, Ferrante et al. 
 [40] demonstrated that a longer colectomy-free survival 
was observed among UC patients who achieved MH (de-
fined as a Mayo endoscopic subscore of 0 or 1) at week 4 
or week 10. 
 Hence, MH is associated with a reduced need for sur-
gery in both CD and UC  [36] .
 Colorectal Cancer 
 In a case-control study of 68 UC patients and 136 
matched controls, the histological inflammation score 
was the only independent risk factor for the development 
of colorectal neoplasia (OR 4.69, 95% CI 2.10–10.48, p  ! 
0.001)  [41] . 
 In a subsequent study, the same authors showed that 
macroscopically normal endoscopic findings returned 
the 5-year cancer risk to that of the general population 
(OR 0.38, 95% CI 0.19–0.73, p = 0.003)  [42] . Rubin et al. 
[43] also demonstrated a higher risk of cancer and dys-
plasia in UC patients with a higher inflammatory activ-
ity score (OR 2.73, 95% CI 1.44–5.18, p = 0.002). Gupta et 
al.  [44]  confirmed that histological inflammation over 
time was associated with the progression towards ad-
vanced neoplasia in UC (HR 3, 95% CI 1.4–6.3).
 MH is thus associated with a lower risk of colorectal 
cancer in UC; for CD, such data are lacking  [36] .
 Conclusion 
 The definition of MH is still under debate and no for-
mal definition has been universally accepted. Except for 
CDEIS, all endoscopic indices still lack validation in both 
CD and UC. Anti-TNF therapy is the most potent drug 
class to induce and maintain MH in IBD. MH may change 
the natural course of the disease by decreasing the need 
for surgery and reducing hospitalization rates in both UC 
and CD. MH may also prevent the development of long-
term disease complications, such as bowel damage in CD 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
15
/2
01
6 
6:
00
:1
0 
PM
 Mucosal Healing with Anti-TNF 
Antibodies  
Digestion 2012;86(suppl 1):16–22 21
and colorectal cancer in UC. Schnitzler et al.  [11] showed 
that MH predicts long-term outcome with maintenance 
therapy with infliximab in CD. The need for surgery was 
significantly different between the groups with and with-
out MH (14 and 38.4%, respectively, p  ! 0.0001). Interest-
ingly, there was no difference between the groups with 
complete and partial MH (14 vs. 14.1%, respectively). 
Hence, further investigation is required in order to estab-
lish the degree of MH needed to change the course of dis-
ease.
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